<DOC>
<DOCNO>EP-0634396</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Amino acid derivatives and their use as inhibitors of encephalinase
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31343	C07D31762	A61P4300	C07D31158	C07C32700	A61K3121	C07C32360	A61K3122	C07D30700	C07C31900	A61K31165	C07D31918	C07C32732	A61P2504	C07D31100	C07C31920	A61K3136	A61K3134	A61K31357	A61K31335	A61K31195	A61K31185	C07D31900	A61P4300	C07D30778	A61K31265	C07C32300	A61K31165	A61K31343	A61K3123	C07D31700	A61P2500	A61K31357	A61K31335	C07C32350	C07D31760	A61K3134	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	C07D	A61P	C07D	C07C	A61K	C07C	A61K	C07D	C07C	A61K	C07D	C07C	A61P	C07D	C07C	A61K	A61K	A61K	A61K	A61K	A61K	C07D	A61P	C07D	A61K	C07C	A61K	A61K	A61K	C07D	A61P	A61K	A61K	C07C	C07D	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	C07D317	A61P43	C07D311	C07C327	A61K31	C07C323	A61K31	C07D307	C07C319	A61K31	C07D319	C07C327	A61P25	C07D311	C07C319	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	C07D319	A61P43	C07D307	A61K31	C07C323	A61K31	A61K31	A61K31	C07D317	A61P25	A61K31	A61K31	C07C323	C07D317	A61K31	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
New amino acid derivatives, processes for their preparation and their therapeutic application. Amino acid derivatives corresponding to the general formulae: 
<
IMAGE
>
   
<
IMAGE
>
   These derivatives can be used as medicaments which have an enkephalinase-inhibiting activity.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
BIOPROJET SOC CIV
</APPLICANT-NAME>
<APPLICANT-NAME>
SOCIETE CIVILE BIOPROJET
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
DANVY DENIS
</INVENTOR-NAME>
<INVENTOR-NAME>
DUHAMEL LUCETTE
</INVENTOR-NAME>
<INVENTOR-NAME>
DUHAMEL PIERRE
</INVENTOR-NAME>
<INVENTOR-NAME>
GROS CLAUDE
</INVENTOR-NAME>
<INVENTOR-NAME>
LECOMTE JEANNE-MARIE
</INVENTOR-NAME>
<INVENTOR-NAME>
LUSSON CHRISTOPHE
</INVENTOR-NAME>
<INVENTOR-NAME>
MONTEIL THIERRY
</INVENTOR-NAME>
<INVENTOR-NAME>
NOEL NADINE
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHWARTZ JEAN-CHARLES
</INVENTOR-NAME>
<INVENTOR-NAME>
DANVY, DENIS
</INVENTOR-NAME>
<INVENTOR-NAME>
DUHAMEL, LUCETTE
</INVENTOR-NAME>
<INVENTOR-NAME>
DUHAMEL, PIERRE
</INVENTOR-NAME>
<INVENTOR-NAME>
GROS, CLAUDE
</INVENTOR-NAME>
<INVENTOR-NAME>
LECOMTE, JEANNE-MARIE
</INVENTOR-NAME>
<INVENTOR-NAME>
LUSSON, CHRISTOPHE
</INVENTOR-NAME>
<INVENTOR-NAME>
MONTEIL, THIERRY
</INVENTOR-NAME>
<INVENTOR-NAME>
NOEL, NADINE
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHWARTZ, JEAN-CHARLES
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Amino acid derivatives, characterised in that they correspond to the
general formulae



in which R
1
 represents a hydrogen atom, a phenyl group optionally mono- or
polysubstituted with a halogen atom, a trifluoromethyl group, a nitro

group, a cyano group or an amino group, a lower alkyl group, a lower
phenylalkylene group; the grouping



where R'
1
 represents a hydrogen atom, a lower alkyl group, a phenyl group,
a lower phenylalkylene group; a grouping



where A, B and n
3
 denote the following

A
B
n
3
0
0
1
0
CH
2
1
CH
2
CH
2
1
0
0
2 
CH
2
CH
2
2
0
CH
2
2

a biphenyl, alpha and beta naphthyl group,

n
1
 varies from 0 to 10,
n
2
 varies from 1 to 10,
R
2
 represents a hydrogen atom, a lower alkyl group, a lower hydroxyalkylene
group, a phenyl group, a lower phenylalkylene group, a lower

hydroxyphenylalkylene group, a lower aminoalkylene group, a lower
guanidinoalkylene group, a lower mercaptoalkylene group, a lower

thioalkylene-lower alkyl group, a lower imidazolylalkylene group, a lower
indolylalkylene group, a lower carbamoylalkylene group, a lower

carboxyalkylene group;
R
3
 likewise represents a hydrogen atom or a lower alkyl group;
R
4
 represents a hydrogen atom, a straight or branched-chain aliphatic acyl
radical, an optionally mono- or polysubstituted aromatic acyl radical or a

straight or branched-chain acyl radical containing one or more oxygen
atoms;
R
5
 represents a hydrogen atom, a straight or branched-chain lower alkyl
group, a phenyl group, a lower phenylalkylene group, with the latter two

groups being optionally mono- or polysubstituted in the phenyl ring, a
straight or branched-chain substituent containing one or more oxygen atoms,

with the terms "lower alkyl" or "lower alkylene" denoting respectively a
straight or branched-chain alkyl or alkylene group having 1 to 6 carbon

atoms, preferably 1 to 4 carbon atoms.
Amino acid derivatives according to Claim 1, characterised in that R
1

represents a phenyl group which is optionally mono- or polysubstituted with
a halogen atom, or with the trifluoromethyl group; the grouping



where R'
1
 represents a lower alkyl group, a phenyl group; the grouping 


where A and B represent oxygen, and n
3
 is equal to 1 or 2; a biphenyl,
alpha and beta naphthyl group;


R
2
 and R
3
 represent a hydrogen atom, a lower alkyl radical;
R
4
 represents a hydrogen atom, a straight or branched-chain aliphatic acyl
radical or an aromatic acyl radical;
R
5
 represents a hydrogen atom, a lower alkyl radical, a phenyl radical;
n
1
 is equal to 0 or 1;
n
2
 is equal to 1 or 2.
Amino acid derivatives according to Claim 1, characterised in that
they are selected from among:


N-(E)-[1-oxo 2-(acetylthiomethyl) 3-phenyl propenyl]-β-alanine benzyl

ester,
N-(E)-[1-oxo 2-(acetylthiomethyl) 3-phenyl propenyl]-β-alanine methyl

ester,
N-(E)-[1-oxo 2-(acetylthiomethyl) 3-phenyl propenyl]-β-alanine ethyl

ester,
N-(E)-[1-oxo 2-(mercaptomethyl) 3-phenyl propenyl]-β-alanine,
N-(E)-[1-oxo 2-(benzoylthiomethyl) 3-phenyl propenyl]-β-alanine benzyl

ester,
N-(E)-[1-oxo 2-(benzoylthiomethyl) 3-phenyl propenyl]-β-alanine methyl

ester,
N-(E)-[1-oxo 2-(benzoylthiomethyl) 3-phenyl propenyl]-β-alanine ethyl

ester,
N-(E)-[1-oxo 2-(pivaloylthiomethyl) 3-phenyl propenyl]-β-alanine

benzyl ester,
N-(E)-[1-oxo 2-(pivaloylthiomethyl) 3-phenyl propenyl]-β-alanine

methyl ester,
N-(E)-[1-oxo 2-(pivaloylthiomethyl) 3-phenyl propenyl]-β-alanine ethyl

ester,
N-(E)-[1-oxo 2-(acetylthiomethyl) 3-phenyl propenyl]-(RS)-3-aminobutyric

acid methyl ester, 
N-(E)-[1-oxo 2-(mercaptomethyl) 3-phenyl propenyl]-(RS)-3-aminobutyric

acid,
N-(E)-[1-oxo 2-(acetylthiomethyl) 3-phenyl propenyl]-(RS)-3-amino-2-methylpropionic

acid methyl ester,
N-(E)-[1-oxo 2-(mercaptomethyl) 3-phenyl propenyl]-(RS)-3-amino-2-methylpropionic

acid,
N-(E)-[1-oxo 2-(acetylthiomethyl) 3-phenyl propenyl]-4-aminobutyric

acid benzyl ester,
N-(E)-[1-oxo 2-(mercaptomethyl) 3-phenyl propenyl]-4-aminobutyric

acid,
N-(Z)-[1-oxo 2-(acetylthiomethyl) 3-(4-methoxyphenyl) propenyl]-β-alanine

benzyl ester,
N-(E)-[1-oxo 2-(acetylthiomethyl) 3-(4-methoxyphenyl) propenyl]-β-alanine

benzyl ester,
N-(E)-[1-oxo 2-(mercaptomethyl) 3-(4-methoxyphenyl) propenyl]-β-alanine,
N-(Z)-[1-oxo 2-(acetylthiomethyl) 3-(4-trifluoromethyl phenyl)
propenyl]
-β-alanine benzyl ester,
N-(E)-[1-oxo 2-(acetylthiomethyl) 3-(4-trifluoromethyl phenyl)
propenyl]
-β-alanine benzyl ester,
N-(E)-[1-oxo 2-(mercaptomethyl) 3-(4-trifluoromethyl phenyl)
propenyl]
-β-alanine,
N-(Z)-[1-oxo 2-(acetylthiomethyl) 3-(4-phenyl phenyl) propenyl]-β-alanine

benzyl ester,
N-(E)-[1-oxo 2-(acetylthiomethyl) 3-(4-phenyl phenyl) propenyl]-β-alanine

benzyl ester,
N-(E)-[1-oxo 2-(mercaptomethyl) 3-(4-phenyl phenyl) propenyl]-β-alanine,
N-(Z)-[1-oxo 2-(acetylthiomethyl) 3-(4-ethoxy phenyl) propenyl]-β-alanine

benzyl ester,
N-(E)-[1-oxo 2-(acetylthiomethyl) 3-(4-ethoxy phenyl) propenyl]-β-alanine

benzyl ester,
N-(E)-[1-oxo 2-(mercaptomethyl) 3-(4-ethoxy phenyl) propenyl]-β-alanine,
N-(Z)-[1-oxo 2-(acetylthiomethyl) 3-(4-propoxy phenyl) propenyl]-β-alanine

benzyl ester,
N-(E)-[1-oxo 2-(acetylthiomethyl) 3-(4-propoxy phenyl) propenyl]-β-alanine

benzyl ester,
N-(Z)-[1-oxo 2-(acetylthiomethyl) 3-(3,5-difluoro phenyl) propenyl]-β-alanine

benzyl ester,
N-(E)-[1-oxo 2-(acetylthiomethyl) 3-(3,5-difluoro phenyl) propenyl]-β-alanine

benzyl ester, 
N-(E)-[1-oxo 2-(mercaptomethyl) 3-(3,5-difluoro phenyl) propenyl]-β-alanine,
N-(Z)-[1-oxo 2-(acetylthiomethyl) 3-(1-naphthyl) propenyl]-β-alanine

benzyl ester,
N-(E)-[1-oxo 2-(acetylthiomethyl) 3-(1-naphthyl) propenyl]-β-alanine

benzyl ester,
N-(E)-[1-oxo 2-(mercaptomethyl) 3-(1-naphthyl) propenyl]-β-alanine,
N-(Z)-[1-oxo 2-(acetylthiomethyl) 3-phenyl propenyl]-β-alanine benzyl

ester,
N-(Z)-[1-oxo 2-(mercaptomethyl) 3-phenyl propenyl]-β-alanine,
N-(Z)-[1-oxo 2-(acetylthiomethyl) 3-(4-phenoxy phenyl) propenyl]-β-alanine

benzyl ester,
N-(E)-[1-oxo 2-(acetylthiomethyl) 3-(4-phenoxy phenyl) propenyl]-β-alanine

benzyl ester,
N-(E)-[1-oxo 2-(mercaptomethyl) 3-(4-phenoxy phenyl) propenyl]-β-alanine,
N-(Z)-[1-oxo 2-(acetylthiomethyl) 3-(3,4-methylene dioxyphenyl)
propenyl]
-β-alanine benzyl ester,
N-(E)-[1-oxo 2-(acetylthiomethyl) 3-(3,4-methylene dioxyphenyl)
propenyl]
-β-alanine benzyl ester.
A process for the preparation of the amino acid derivatives of the
formula (Ib) in which R
1
, R
2
, R
3
, R
4
, R
5
, n
1
, n
2
 and n
3
 denote the same as
indicated in Claim 1, characterised in that it comprises successively:


a) carrying out an allylic bromination of an ethylenic acid of the

configuration (E) of the formula (II)


in which R
1
 denotes the same as above, using a brominating agent such as N-bromosuccinimide
in the presence of a catalytic quantity of benzoyl

peroxide, in order to form an acid of the formula (III)

b) substituting the bromine of the acid of the formula (III), preferably
with an R
4
-SH thioacid, in order to form the thioacylated ethylenic acid of
the configuration (Z) of the formula (IV)



where R
4
 has the definition indicated in Claim 1,
c) coupling the acid of the formula (IV) with the salt of the desired
amino ester of the formula (V)



where R
2
, R
3
, R
5
 and n
2
 denote the same as indicated in Claim 1, and X
represents, for example, halides, benzene sulphonate, methane sulphonate

and toluene sulphonate, in order to form the compound of the configuration
(Z) of the formula (Ib)



where R
4
 and R
5
 are not hydrogen atoms,
d) removing by alkaline means the protection of the compound of the
formula (Ib), in order to form the compounds of the configuration (Z) of

the formula (Ib) where R
4
 and R
5
 are hydrogen atoms 

A process for the preparation of the amino acid derivatives of the
formula (Ia) where R
1
, R
2
, R
3
, R
4
, R
5
, n
1
, n
2
 and n
3
 denote the same as
indicated in Claim 1, characterised in that it comprises successively:


a) isomerising the ethylenic acid of the configuration (Z) of the formula
(IV)



where R
1
, R
4
 and n
1
 denote the same as indicated in Claim 1, then separating
the (E/Z) isomer mixture obtained, using an amine such as cyclohexylamine,

in order to obtain the thioacylated ethylenic acid of the configuration (E)
of the formula (VI)


b) coupling the acid of the formula (VI) with the salt of the desired
amino ester of the formula (V), in the presence of a coupling agent such as

dicyclohexyl carbodiimide, in order to obtain the compound of the formula
(Ia) of the configuration (E) where R
4
 and R
5
 are not hydrogen atoms

c) then removing by alkaline means the protection of the compound of the
formula (Ia), in order to obtain the compounds of the configuration (E) of

the formula (Ia) where R
4
 and R
5
 are hydrogen atoms

A process for the preparation of the amino acid derivatives of the
formula (Ia) where R
1
, R
2
, R
3
, R
4
, R
5
, n
1
, n
2
 and n
3
 denote the same as
indicated in Claim 1, characterised in that it comprises successively:


a) isomerising the ethylenic acid of the formula (IV) which has a (Z)
configuration, in order to obtain the thioacylated ethylenic acid in the

form of a mixture of isomers of the configuration (Z/E) of the formula
(VII)



where R
1
, R
4
 and n
1
 denote the same as indicated in Claim 1,
b) coupling the acid of the formula (VII) with the salt of the desired
amino ester of the formula (V), in the presence of a coupling agent such as

dicyclohexyl carbodiimide, in order to obtain the compound of the formula
(VIII) which is constituted by a (Z/E) isomer mixture


c) separating the (Z/E) isomer mixture of the compound of the formula
(VIII), for example by flash chromatography with silica or by fractional

recrystallisation, in order to obtain the compound of the configuration (E)
of the formula (Ia) where R
4
 and R
5
 are not hydrogen atoms 

A process for the preparation of the amino acid derivatives of the
formula (Ia) where R
1
, R
2
, R
3
, R
4
, R
5
, n
1
, n
2
 and n
3
 denote the same as
indicated in Claim 1, with R
4
 and R
5
 not being hydrogen atoms,
characterised in that it comprises successively:


a) isomerising the compound of the formula (Ib) which has a double bond
and the configuration (Z)



preferably in the presence of boron trifluoride etherate, in order to
obtain the compound of the formula (VIII) which is constituted by a (Z/E)

isomer mixture

b) separating the (Z/E) isomer mixture of the compound of the formula
(VIII) in order to obtain the compound of the configuration (E) of the

formula (Ia) where R
4
 and R
5
 are not hydrogen atoms

A medicament having an encephalinase-inhibiting activity,
characterised in that it contains as the active principle a compound

according to any one of Claims 1 to 3.
A medicament according to Claim 8, characterised in that it is
presented in the form of unit doses containing from 20 to 200 mg of active

principle.
</CLAIMS>
</TEXT>
</DOC>
